GPRC5D Protein: An Emerging Orphan Receptor Target for Immunotherapy in Multiple Myeloma

Author: Senior Product Manager of UA Views：8

This article focuses on the molecular characteristics and immunotherapeutic target value of G protein-coupled receptor class C group 5 member D (GPRC5D), systematically elaborating its gene localization, structural composition, and homodimeric assembly as an orphan class C GPCR, analyzing its distribution characteristics of being confined to hair follicle regions in normal tissues while being highly specifically overexpressed on the surface of malignant plasma cells in multiple myeloma and its relationship of independent expression from BCMA, and exploring the preclinical and clinical activity of bispecific antibodies and CAR-T cell therapies targeting GPRC5D.

Recent Advances
Product Information

Recent Advances

GPRC5D Protein: An Emerging Orphan Receptor Target for Immunotherapy in Multiple Myeloma

Summary: This article focuses on the molecular characteristics and immunotherapeutic target value of G protein-coupled receptor class C group 5 member D (GPRC5D), systematically describing its gene localization, structural composition, and homodimer assembly as an orphan class C GPCR, analyzing its distribution features of restricted expression in the hair follicle region in normal tissues and highly specific overexpression on the surface of malignant plasma cells in multiple myeloma as well as its relationship of mutual independence from BCMA expression, and discussing the preclinical and clinical activity of bispecific antibodies and CAR-T cell therapies targeting GPRC5D.

I. Molecular Localization and Orphan Receptor Attributes of GPRC5D.

GPRC5D belongs to the class C family of G protein-coupled receptors and is an orphan receptor with unknown physiological function. Its gene is located at chromosome 12p13.1, encodes a total of 345 amino acids, and has a molecular weight of approximately 38.8 kDa. From the perspective of receptor classification, an orphan receptor means that its endogenous ligand has not yet been identified. This characteristic not only leaves a gap for functional research but also provides a unique entry point for drug development——therapeutic strategies targeting GPRC5D can bypass regulation of the ligand-receptor signaling pathway and instead directly exploit its cell surface expression as a target for immune recognition. This positioning distinguishes the development logic of GPRC5D from traditional GPCR drugs and brings it closer to the targeted therapy paradigm for tumor surface antigens.

II. Structural Features and Dimer Assembly of GPRC5D.

GPRC5D is an orphan class C GPCR. Its core transmembrane protein contains approximately 308 residues and has a short N-terminal extracellular region of about 20 to 50 amino acids, lacking the large Venus flytrap domain typical of classic class C GPCRs. This structural absence has important functional implications: classic class C GPCRs such as metabotropic glutamate receptors rely on the large Venus flytrap domain to recognize ligands, whereas GPRC5D lacks this domain, suggesting that its activation mechanism and ligand recognition mode are fundamentally different from those of classic family members, which is also consistent with its identity as an orphan receptor.

In terms of structural organization, GPRC5D forms a symmetric homodimer through the TM4-TM4/5 interface, which is stabilized by cholesterol molecules. Cholesterol, as a structural component stabilizing the dimer interface, reflects the receptor's dependence on the membrane lipid environment. In addition, GPRC5D has an abnormally short ECL2, forming an exposed shallow extracellular pocket, and exhibits weak Gi/o activity in the inactive conformation. The shallow extracellular structure formed by the abnormally short ECL2 may provide an accessible epitope region for recognition by macromolecules such as antibodies and CARs, and this structural feature is closely related to its feasibility as an immunotherapeutic target.

III. Specific High Expression of GPRC5D in Multiple Myeloma.

As an emerging drug target for multiple myeloma, GPRC5D is expressed in normal tissues only in the hair follicle region; on the surface of malignant myeloma cell lines, it is specifically highly expressed. The core value of this expression profile lies in the dual safeguard of tumor selectivity: normal tissue expression is restricted to the hair follicle, an immune-privilege-related region, while malignant plasma cells show highly specific overexpression on their surface, forming a significant therapeutic window between the two.

More critically, GPRC5D has been shown to be expressed on the cell membrane independently of BCMA, and it can serve as a complementary drug target for existing BCMA-targeted therapies, becoming another immune barrier for patients with multiple myeloma. In the treatment of multiple myeloma, although BCMA-targeted therapies have achieved significant efficacy, antigen escape leading to loss of BCMA expression is an important mechanism of drug-resistant relapse. The independence of GPRC5D and BCMA expression means that even if tumor cells lose BCMA due to BCMA-targeted therapy, their GPRC5D expression may still be retained, thereby providing an alternative immune attack target for patients who relapse after BCMA treatment. High GPRC5D levels are associated with shorter progression-free survival, further suggesting that its expression level is not only a basis for selecting therapeutic targets but may also serve as a reference indicator for prognostic assessment.

IV. Research Application Value of GPRC5D Protein

As an orphan receptor in the class C GPCR family whose physiological function has not yet been elucidated, GPRC5D has become a highly promising emerging target in the field of multiple myeloma immunotherapy by virtue of its gene localization at chromosome 12p13.1, its structural features of a short N-terminus and a transmembrane core of approximately 308 residues lacking a Venus flytrap domain, its symmetric homodimer assembly formed through the TM4-TM4/5 interface and stabilized by cholesterol, and its distribution features of restricted expression in the hair follicle in normal tissues and highly specific overexpression on the surface of malignant plasma cells in multiple myeloma independent of BCMA expression. From clinical activity validation of bispecific antibodies and CAR-T cells to the advancement of clinical trials of targeted drugs, from the value as an alternative target after BCMA therapy resistance to the prognostic association between high expression and shortened progression-free survival, GPRC5D continues to drive the in-depth development of the field of multiple myeloma immunotherapy.

V. Conclusion.

In basic research and immunotherapeutic drug development related to GPRC5D, high-quality recombinant GPRC5D protein is a core tool for dissecting its structural features, evaluating the binding activity of targeted antibodies and CARs, and conducting epitope analysis. As a multi-transmembrane protein, the in vitro recombinant expression and purification of GPRC5D require balancing the conformational integrity and solubility of membrane proteins, and detergent-form products provide a feasible solution to this challenge. The dual Flag and His tags facilitate purification through anti-Flag affinity chromatography and immobilized metal affinity chromatography, and enable detection and capture with corresponding antibodies. To meet the needs of GPRC5D functional research and multiple myeloma targeted therapy development, UA provides GPRC5D Flag&His Tag Protein, Human. This product is suitable for application scenarios such as binding activity analysis of GPRC5D with targeted antibodies and CAR molecules, research on GPRC5D homodimer assembly and structural features, in vitro evaluation of bispecific antibodies and CAR-T cell therapies targeting GPRC5D, and GPRC5D epitope identification.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Next